Monday, September 22, 2008
* Patients unable to tolerate aggressive cytoreductive surgery should undergo neoadjuvant chemotherapy first.
* Neoadjuvant chemotherapy should become a standard alternative approach to treating patients with stage IV ovarian cancer.
* Women with stage IIIC disease should be evaluated by a gynecologic oncologist to determine the likelihood of optimal cytoreducibility. If residual macroscopic disease would be expected with surgery alone, the patient should be offered the option of neoadjuvant chemotherapy."
Therapeutic Agents Mentioned in This Article